-
1
-
-
85080598305
-
-
Hellmann A, Prejzner W. [Hypereosinophilic syndrome and chronic eosinophilic leukemia]. In: Szczeklik A, ed. Internal Diseases. 2. Kraków: Medycyna Praktyczna; 2005: 1500-1503. Polish.
-
Hellmann A, Prejzner W. [Hypereosinophilic syndrome and chronic eosinophilic leukemia]. In: Szczeklik A, ed. Internal Diseases. Vol. 2. Kraków: Medycyna Praktyczna; 2005: 1500-1503. Polish.
-
-
-
-
2
-
-
34249732053
-
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
-
Jovanovic JV, Score J, Waghom K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007; 109: 4635-4640.
-
(2007)
Blood
, vol.109
, pp. 4635-4640
-
-
Jovanovic, J.V.1
Score, J.2
Waghom, K.3
-
3
-
-
16344392969
-
Targeted imatinib therapy in a patient with chronic eosinophilic leukemia]
-
Polish
-
Prejzner W, Szatkowski D, Wasa̧g B, et al. [Targeted imatinib therapy in a patient with chronic eosinophilic leukemia]. Wspólczesna onkologia. 2005; 9: 7-10. Polish.
-
(2005)
Wspólczesna onkologia
, vol.9
, pp. 7-10
-
-
Prejzner, W.1
Szatkowski, D.2
Wasa̧g, B.3
-
4
-
-
40949147830
-
A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1l1-PDGFRA-expressing patients
-
Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1l1-PDGFRA-expressing patients. Br J Haematol. 2008; 141: 200-204.
-
(2008)
Br J Haematol
, vol.141
, pp. 200-204
-
-
Helbig, G.1
Stella-Hołowiecka, B.2
Majewski, M.3
-
5
-
-
0344987881
-
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
-
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348: 1201-1214.
-
(2003)
N Engl J Med
, vol.348
, pp. 1201-1214
-
-
Cools, J.1
DeAngelo, D.J.2
Gotlib, J.3
-
6
-
-
3042678647
-
Clinical and molecular features of FIP1l1-PDGFRA (+) chronic eosinophilic leukemias
-
Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1l1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia. 2004; 18: 734-742.
-
(2004)
Leukemia
, vol.18
, pp. 734-742
-
-
Vandenberghe, P.1
Wlodarska, I.2
Michaux, L.3
-
7
-
-
8644263305
-
FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
-
Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104: 3038-3045.
-
(2004)
Blood
, vol.104
, pp. 3038-3045
-
-
Pardanani, A.1
Brockman, S.R.2
Paternoster, S.F.3
-
8
-
-
1842474941
-
The FIP1l1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management
-
Gotlib J, Cools J, Malone JM. et al. The FIP1l1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management Blood. 2004; 103: 2879-2891.
-
(2004)
Blood
, vol.103
, pp. 2879-2891
-
-
Gotlib, J.1
Cools, J.2
Malone, J.M.3
|